Eyenovia (NASDAQ:EYEN – Get Free Report) and Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.
Profitability
This table compares Eyenovia and Mirum Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eyenovia | -114,639.41% | -1,108.24% | -139.36% |
| Mirum Pharmaceuticals | -31.69% | -41.22% | -14.81% |
Risk & Volatility
Eyenovia has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eyenovia | 0 | 4 | 0 | 0 | 2.00 |
| Mirum Pharmaceuticals | 0 | 0 | 10 | 1 | 3.09 |
Eyenovia currently has a consensus target price of $2.00, indicating a potential upside of 3,094.89%. Mirum Pharmaceuticals has a consensus target price of $57.10, indicating a potential upside of 21.62%. Given Eyenovia’s higher possible upside, analysts plainly believe Eyenovia is more favorable than Mirum Pharmaceuticals.
Earnings and Valuation
This table compares Eyenovia and Mirum Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eyenovia | N/A | N/A | -$27.26 million | ($0.73) | -0.09 |
| Mirum Pharmaceuticals | $186.37 million | 12.09 | -$163.41 million | ($2.02) | -23.24 |
Eyenovia has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
25.8% of Eyenovia shares are held by institutional investors. 7.1% of Eyenovia shares are held by company insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Mirum Pharmaceuticals beats Eyenovia on 8 of the 14 factors compared between the two stocks.
About Eyenovia
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.
